In addition, patients with elevated levels of NUDT1, 2, 5 or 16 exhibit significantly poorer overall survival in HR-positive breast cancer (Figure 1a−d center) [25] but not HR-negative breast cancer (Figure 1a−d right). This evidence concerns the gene NUDT1 and breast cancer.